<DOC>
	<DOCNO>NCT01009983</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel carboplatin , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , panitumumab , block tumor growth different way . Some block ability tumor cell grow spread . Other find tumor cell help kill carry tumor-killing substance . Giving panitumumab together paclitaxel carboplatin may better way block tumor growth . PURPOSE : This phase II trial study side effect well paclitaxel carboplatin together panitumumab work treat patient metastatic triple negative breast cancer .</brief_summary>
	<brief_title>Paclitaxel , Carboplatin , Panitumumab Treating Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVE : I . To determine response rate combination carboplatin , paclitaxel panitumumab woman ER- , PR- Her-2 negative metastatic breast cancer . SECONDARY OBJECTIVES : I . To determine tolerability toxicity combination paclitaxel , carboplatin panitumumab . II . To determine marker co-occur EGFR expression triple negative breast cancer . III . To assess association tumor biomarkers clinical outcome ( response survival ) . IV . To examine effect regimen time progression survival . OUTLINE : Patients receive paclitaxel IV carboplatin IV day 1 , 8 , 15 . Patients also receive panitumumab IV day 1 15 . Treatment repeat every 28 day 3 course absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion Pathologically confirm invasive breast cancer ER &lt; 10 % , PR &lt; 10 % , IHC , HER2 1+ 0 FISH negative Measurable ( &gt; = 1 cm ) assessable disease detectable imagine physical exam Patients bone disease measurable lesion xray , MRI , CT scan Only one prior therapy metastatic recurrent breast cancer allow Prior chemotherapy radiation therapy permit least 2 week elapse prior study enrollment Prior therapy bevacizumab permit least 2 week elapse prior study enrollment Prior therapy bevacizumab permit least 28 day elapse last bevacizumab treatment prior study enrollment ECOG PS 01 Signed protocol specific inform consent prior registration Life expectancy great 3 month Please contact study investigator and/or consult protocol document specific laboratory criterion Tissue block available primary breast cancer Premenopausal woman must negative serum urine pregnancy test prior start study treatment ( postmenopausal define &gt; 6 month amenorrhea prior hysterectomy ) Exclusion More equal 2 prior regimen metastatic breast cancer Leptomeningeal disease Brain metastasis except solitary lesion resect treated gamma knife residual disease CT MRI receive whole brain RT f/u MRI normal residual neurologic deficit History interstitial lung disease ( ie pneumonitis , pulmonary fibrosis ) evidence interstitial lung disease baseline chest computerize tomography ( CT ) scan History irreversible neuropathy Another malignancy carcinoma situ cervix skin cancer Active uncontrolled bacterial viral fungal infection Active pregnancy breast feeding Patients preexist neuropathy &gt; = grade 2 History myocardial infarction , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia Patients previous history CTCAE grade &gt; = 3 hypersensitivity paclitaxel Cremophor EL eligible</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>triple-negative breast cancer</keyword>
</DOC>